Marijuana

Mula sa Wikipediang Tagalog, ang malayang ensiklopedya
(Idinirekta mula sa Marihuwana)
Tumalon sa: nabigasyon, hanapin
Marijuana
Cannabis Plant.jpg
Namumulaklak na halamang Cannabis
Botanical Cannabis
Mga pinagmulang halaman Cannabis sativa, Cannabis indica, Cannabis ruderalis
Part(s) of plant bulaklak
Pinagmulang heograpiko Sentral Asya at Timog Asya.[1]
Mga aktibong sangkap Tetrahydrocannabinol, Cannabidiol, Cannabinol, Tetrahydrocannabivarin
Mga pangunahing prodyuser Afghanistan, Burma, Canada, China, Colombia, India, Jamaica, Laos, Mexico, Netherlands, Pakistan, Paraguay,[2] Thailand, Turkey, United States
Mga pangunahing konsumer Buong mundo

Ang marijuana (mula sa Mehikanong Espanyol na marihuana) o sa Ingles ay cannabis ay isang preparasyon ng halamang cannabis na ginagamit bilang sikoaktibo at gamot o medisina. Ang pangunahing sikoaktibong sangkap na kompuwesto nito ang tetrahydrocannabinol (THC) na isa sa 483 alam na kompuwesto ng halamang ito. [3] May iba pang mga 84 cannabinoid dito gaya ng cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV)[4][5] at cannabigerol (CBG).

Ang marijuana ay kadalasang kinokonsumo dahil sa mga epektong sikoaktibo at pisiolohikal nito na kinabibilangan ng tumaas na mood o pakiramdam o euphoria, relaksasyon [6] at tumaas na gana [7]

Ang marijuana ay ginagamit bilang drogang panlibangan o medisina gayundin bilang bahagi ng mga ritong pang-relihiyon. Ang pinakamaagang paggamit nito ay mula ika-3 milenyo BCE. [8] Simula ika-20 siglo, ang pag-aangkin ng marijuana ay ipinagbabawal o ilegal sa maraming mga bansa sa buong mundo. [9][10] Noong 2004, ang paggamit ng marijuana sa buong mundo ay tinatayang 4% ng populasyon ng mundo o mga 162 milyong katao at ang tinatayang 0.6% (22.5 milyong katao) ay gumagamit nito sa araw-araw.[11]

Mekanismo[baguhin]

Ang mekanismo ng marijuana sa tao ay naunawaan lamang sa huli ng ika-20 siglo. Ang THC ng marijuana ay umaasal sa dalawang uri ng mga cannabinoid receptor sa tao na CB1 receptor at CB2 receptor na parehong G-Protein coupled receptor. Ang CB1 receptor ay matatagpuan sa utak at sa ilang mga peripheral tissue at ang CB2 receptor ay matatagpuan sa mga peripheral tissue gayundin sa mga selulang neuroglial. Ang mga cannabinoid receptor ay pinapagana ng mga cannabinoid na maaaring nalilikha mula sa loob ng katawan ng tao (endocannabinoid) o ipinakilala sa katawan ng tao gaya ng pagkonsumo ng marijuana o ibang mga sintetiko nito.

Epekto[baguhin]

Ang mga kanais nais na epekto nito ay relaksasyon at katamtamang euphoria (pakiramdam na "high").

Ang mga hindi kanais nais na epekto nito ang nabawasang panandaliang memorya, tuyong bibig, huminang kakayahan ng paggalaw, pamumula ng mga mata.

Kabilang din sa mga epekto ang tumaas na tibok ng puso, tumaas na gana sa pagkain, bumabang presyon ng dugo.

Pagiging adiktibo[baguhin]

Ayon kay Dr. Jack E. Henningfield ng National Institute on Drug Abuse, sa mga nirangguhang 6 na sustansiya sa kanilang pagiging adiktibo (marijuana, caffeine, cocaine, alak, heroin at nicotine), ang marijuana ang pinaka-hindi adiktibo, ang caffeine ang ikalawang pinaka-hindi adiktibo at ang nicotine ang pinaka-adiktibo. [12]

Paggamit medikal[baguhin]

Medikal na marijuana

Ang marijuana ay ginawang legal sa 18 estado ng Estados Unidos at Distrito ng Columbia para sa paggamit medikal. Kabilang sa medikal na paggamit ng marijuana ang pagpapaginhawa ng nausea at pagsusuka, stimulasyon ng gutom sa kemoterapiya at mga pasyenteng may AIDS, bumabang presyon sa matang intraokular at para sa pangkalahatang pagpapaginhawa ng mga kirot sa katawan. Ang kompuwesto ng marijuana ay epektibo rin para gamutin ang schizophrenia ayon sa mga siyentipiko.

Ang marijuanang pang medikal ay natagpuang nagpaginhawa ng mga ilang sintomas ng multiple sclerosis[13] at spinal cord injuries[14][15][16][17][18].

Ang ibang mga pag-aaral ay nagsasaad na ang marijuana o mga cannabinoid ay magagamit sa paggamot ng pag-abuso ng alak,[19] amyotrophic lateral sclerosis,[20][21] collagen-induced arthritis,[22] asthma,[23] atherosclerosis,[24] bipolar disorder,[25][26] colorectal cancer,[27] HIV-Associated Sensory Neuropathy,[28] depression,[29][30][31][32] dystonia,[33] epilepsy,[34][35][36] digestive diseases,[37] gliomas,[38][39] hepatitis C,[40] Huntington's disease,[41][42] leukemia,[43] skin tumors,[44] methicillin-resistant Staphylococcus aureus (MRSA),[45] Parkinson's disease,[46] pruritus,[47][48] posttraumatic stress disorder (PTSD),[49] psoriasis,[50] sickle-cell disease,[51] sleep apnea,[52] at anorexia nervosa.[53]

Epekto sa kanser[baguhin]

Natagpuan ng isang pag-aaral ng Universidad Complutense de Madrid na ang mga kimikal sa marijuana ay nagsanhi ng kamatayan ng mga selulang kanser ng utak ng tao. Sa mga selulang kanser ng utak ng tao na nilagay sa mga daga na ginamot ng kimikal ng marijuana, ang tumor ay lumiit. Natagpuan ng pag-aaral nila na ang THC ay nag-alis ng mga selulang kanser nang walang masamang epekto sa mga malusog na selula. [54]

Ayon sa pag-aaral ng California Pacific Medical Center Research Institute noong 2007 at 2010, ang cannabidiol ay nagpahinto sa kanser sa suso na kumalat sa buong katawan sa pamamagitan ng downregulation ng isang gene na tinatawag na ID1.[55][56]

Mga sanggunian[baguhin]

  1. Mahmoud A. ElSohly (2007). Marijuana and the Cannabinoids. Springer. p. 8. ISBN 978-1-59259-947-9. http://books.google.com/books?id=fxoJPVNKYUgC&pg=PA8. 
  2. Sanie Lopez Garelli (25 November 2008). "Mexico, Paraguay top pot producers, U.N. report says". CNN International. http://edition.cnn.com/2008/WORLD/americas/11/25/paraguay.mexico.marijuana/. Nakuha noong 28 September 2013. 
  3. Ethan B Russo (2013). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Routledge. p. 28. ISBN 978-1-136-61493-4. http://books.google.com/books?id=qH-2Lj9x7L4C&pg=PP28. 
  4. El-Alfy, Abir T, et al. (Jun 2010). "Antidepressant-like effect of delta-9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L". Pharmacology Biochemistry and Behavior 95 (4): 434–42. doi:10.1016/j.pbb.2010.03.004. . PMID 20332000. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2866040. 
  5. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. (January 2009). "Distinct effects of delta-9-tetrahydrocannabinol and Cannabidiol on Neural Activation during Emotional Processing". Archives of General Psychiatry 66 (1): 95–105. doi:10.1001/archgenpsychiatry.2008.519. PMID 19124693. http://archpsyc.jamanetwork.com/article.aspx?articleid=482939. 
  6. "Marijuana intoxication: MedlinePlus Medical Encyclopedia". Nlm.nih.gov. http://www.nlm.nih.gov/medlineplus/ency/article/000952.htm. Nakuha noong 2013-07-12. 
  7. "Marijuana: Factsheets: Appetite". Adai.uw.edu. http://adai.uw.edu/marijuana/factsheets/appetite.htm. Nakuha noong 2013-07-12. 
  8. Martin Booth (2003). Cannabis: A History. Transworld. p. 36. ISBN 978-1-4090-8489-1. http://books.google.com/books?id=Mjn6sCiHoFIC&pg=PA36. 
  9. "Cannabis: Legal Status". Erowid.org. http://www.erowid.org/plants/cannabis/cannabis_law.shtml. Nakuha noong 2011-10-30. 
  10. UNODC. World Drug Report 2010. United Nations Publication. p. 198. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2010.html. Nakuha noong 2010-07-19. 
  11. United Nations Office on Drugs and Crime (2006) (PDF). Cannabis: Why We Should Care. 1. S.l.: United Nations. p. 14. ISBN 92-1-148214-3. http://www.unodc.org/pdf/WDR_2006/wdr2006_chap2_biggest_market.pdf. 
  12. "Relative Addictiveness of Drugs". The New York Times. Tfy.drugsense.org. 1994-08-02. http://www.tfy.drugsense.org/tfy/addictvn.htm. Nakuha noong 2013-01-03. 
  13. Zajicek J; Fox P; Sanders H; Wright, David; Vickery, Jane; Nunn, Andrew; Thompson, Alan; Uk Ms Research, Group (2003). "Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial". Lancet 362 (9395): 1517–26. doi:10.1016/S0140-6736(03)14738-1. PMID 14615106. http://www.cmcr.ucsd.edu/geninfo/CannabinoidsMS_Lancet11-03.pdf. 
  14. "Spinal Cord Injury and Disease". Therapeutic Uses of Marijuana. Medical Marijuana Information Resource Centre. http://web.archive.org/web/20070825002916/http://www.medicalmarijuanainformation.com/therapeuticuses/patientGroups.php?groupID=19. Nakuha noong 9 August 2009. 
  15. Maurer M, Henn V, Dittrich A, Hofmann A (1990). "Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial". European Archives of Psychiatry and Clinical Neuroscience 240 (1): 1–4. doi:10.1007/BF02190083. PMID 2175265. 
  16. Kogel RW, Johnson PB, Chintam R, Robinson CJ, Nemchausky BA (1995). "Treatment of Spasticity in Spinal Cord Injury with Dronabinol, a Tetrahydrocannabinol Derivative". American Journal of Therapeutics 2 (10): 799–805. doi:10.1097/00045391-199510000-00012. PMID 11854790. 
  17. Hagenbach et al. (Aug 2007). "The treatment of spasticity with delta-9-tetrahydrocannabinol in persons with spinal cord injury". Spinal Cord 45 (8): 551–62. doi:10.1038/sj.sc.3101982. PMID 17043680. http://www.rehab.ch/fileadmin/user_upload/Transfer/REHAB_Aktuell/Hagenbach_-_the_treatment_of_spasticity_with_A9-tetrahydrocannabinol_in_persons_with_spinal_cord_injury_-_2007.pdf. 
  18. Mack, Allyson; Janet Elizabeth Joy (2001). Marijuana as Medicine?: The Science Beyond the Controversy. National Academy Press. ISBN 0309065313. 
  19. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND (2005). "Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors". Behavioural Brain Research 164 (2): 206–13. doi:10.1016/j.bbr.2005.06.021. PMID 16140402. 
  20. Carter GT, Rosen BS (2001). "Marijuana in the management of amyotrophic lateral sclerosis". The American Journal of Hospice & Palliative Care 18 (4): 264–70. doi:10.1177/104990910101800411. PMID 11467101. 
  21. Weydt P, Hong S, Witting A, Möller T, Stella N, Kliot M (2005). "Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 6 (3): 182–4. doi:10.1080/14660820510030149. PMID 16183560. 
  22. Malfait AM; Gallily R; Sumariwalla PF; Malik, AS; Andreakos, E; Mechoulam, R; Feldmann, M (2000). "The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis". Proceedings of the National Academy of Sciences of the United States of America 97 (17): 9561–6. Bibcode 2000PNAS...97.9561M. doi:10.1073/pnas.160105897. . PMID 10920191. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=16904. 
  23. Tashkin DP, Shapiro BJ, Lee YE, Harper CE (1975). "Effects of smoked marijuana in experimentally induced asthma". The American Review of Respiratory Disease 112 (3): 377–86. PMID 1099949. http://www.druglibrary.org/schaffer/hemp/medical/tashkin/tashkin1.htm. 
  24. Steffens S; Veillard NR; Arnaud C; Pelli, Graziano; Burger, Fabienne; Staub, Christian; Zimmer, Andreas; Frossard, Jean-Louis et al. (16 April 2005). "Cannabis may help keep arteries clear". Nature 434 (7034): 782–6. Bibcode 2005Natur.434..782S. doi:10.1038/nature03389. PMID 15815632. Lay summary – New Scientist. 
  25. Grinspoon L, Bakalar JB (1998). "The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research". Journal of Psychoactive Drugs 30 (2): 171–7. doi:10.1080/02791072.1998.10399687. PMID 9692379. http://www.ukcia.org/research/TheUseofCannabisasaMoodStabilizerinBipolarDisorder.html. 
  26. Ashton CH, Moore PB, Gallagher P, Young AH (2005). "Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential". Journal of Psychopharmacology 19 (3): 293–300. doi:10.1177/0269881105051541. PMID 15888515. 
  27. Patsos HA; Hicks DJ; Dobson RR; Greenhough, A; Woodman, N; Lane, JD; Williams, AC; Paraskeva, C (2005). "The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2". Gut 54 (12): 1741–50. doi:10.1136/gut.2005.073403. . PMID 16099783. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1774787. 
  28. Abrams, D.I., MD; Jay, C.A., MD (2007). "Cannabis in painful HIV-Associated Sensory Neuropathy". Neurology 68 (7): 515–521. doi:10.1212/01.wnl.0000253187.66183.9c. PMID 17296917. http://www.neurology.org/content/68/7/515.abstract. Nakuha noong 2/3/2011. 
  29. Bambico FR, Katz N, Debonnel G, Gobbi G (2007). "Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex". The Journal of Neuroscience 27 (43): 11700–11. doi:10.1523/JNEUROSCI.1636-07.2007. PMID 17959812. Lay summary – Fox News Channel (25 October 2007). 
  30. Denson TF, Earleywine M (2006). "Decreased depression in marijuana users". Addictive Behaviors 31 (4): 738–42. doi:10.1016/j.addbeh.2005.05.052. PMID 15964704. http://www.doctordeluca.com/Library/WOD/WPS3-MedMj/DecreasedDepressionInMjUsers05.pdf. 
  31. Jiang W; Zhang Y; Xiao L; Van Cleemput, J; Ji, SP; Bai, G; Zhang, X (2005). "Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects". The Journal of Clinical Investigation 115 (11): 3104–16. doi:10.1172/JCI25509. . PMID 16224541. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1253627. 
  32. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI (2006). "Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes". The American Journal of Pathology 168 (1): 235–44. doi:10.2353/ajpath.2006.050500. . PMID 16400026. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1592672. 
  33. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM (2002). "Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia". Movement Disorders 17 (1): 145–9. doi:10.1002/mds.1280. PMID 11835452. 
  34. Gray, Richard (10 April 2011). "Cannabis could be used to treat epilepsy". The Daily Telegraph. http://www.telegraph.co.uk/science/science-news/8440303/Cannabis-could-be-used-to-treat-epilepsy.html. Nakuha noong 2011-04-20. 
  35. Marsicano G; Goodenough S; Monory K; Zieglgänsberger, H; Di Marzo, M; Behl, A; Lutz, SC; Cascio, MG et al. (2003). "CB1 cannabinoid receptors and on-demand defense against excitotoxicity". Science 302 (5642): 84–8. Bibcode 2003Sci...302...84M. doi:10.1126/science.1088208. PMID 14526074. 
  36. Bacci A, Huguenard JR, Prince DA (2004). "Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids". Nature 431 (7006): 312–6. Bibcode 2004Natur.431..312B. doi:10.1038/nature02913. PMID 15372034. Lay summary – Science Daily (16 September 2004). 
  37. Di Carlo G, Izzo AA (2003). "Cannabinoids for gastrointestinal diseases: potential therapeutic applications". Expert Opinion on Investigational Drugs 12 (1): 39–49. doi:10.1517/13543784.12.1.39. PMID 12517253. 
  38. Lorente M; Carracedo A; Torres S; Natali, Francesco; Egia, Ainara; Hernández-Tiedra, Sonia; Salazar, María; Blázquez, Cristina et al. (2009). "Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis". Glia 57 (13): 1374–85. doi:10.1002/glia.20856. PMID 19229996. 
  39. Ramer R, Hinz B (2008). "Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1". Journal of the National Cancer Institute 100 (1): 59–69. doi:10.1093/jnci/djm268. PMID 18159069. 
  40. Sylvestre DL, Clements BJ, Malibu Y (2006). "Cannabis use improves retention and virological outcomes in patients treated for hepatitis C". European Journal of Gastroenterology & Hepatology 18 (10): 1057–63. doi:10.1097/01.meg.0000216934.22114.51. PMID 16957511. 
  41. PMID 19228180 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  42. PMID 20590577 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  43. Powles T; te Poele R; Shamash J; Chaplin, T; Propper, D; Joel, S; Oliver, T; Liu, WM (2005). "Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway". Blood 105 (3): 1214–21. doi:10.1182/blood-2004-03-1182. PMID 15454482. 
  44. Casanova ML; Blázquez C; Martínez-Palacio J; Villanueva, Concepción; Fernández-Aceñero, M. Jesús; Huffman, John W.; Jorcano, José L.; Guzmán, Manuel (2003). "Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors". The Journal of Clinical Investigation 111 (1): 43–50. doi:10.1172/JCI16116. . PMID 12511587. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=151833. 
  45. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM (2008). "Antibacterial Cannabinoids from Cannabis sativa: A Structure—Activity Study". J Nat Prod 71 (8): 1427–30. doi:10.1021/np8002673. PMID 18681481. Lay summary – WebMD (4 September 2008). 
  46. Kreitzer AC, Malenka RC (2005). "Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models". Nature 445 (7128): 643–7. doi:10.1038/nature05506. PMID 17287809. Lay summary – Stanford University School of Medicine (7 February 2007). 
  47. Szepietowski JC, Szepietowski T, Reich A (2005). "Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study". Acta Dermatovenerologica Croatica 13 (2): 97–103. PMID 16324422. 
  48. Bergasa NV (2005). "The pruritus of cholestasis". Journal of Hepatology 43 (6): 1078–88. doi:10.1016/j.jhep.2005.09.004. PMID 16253381. 
  49. Ganon-Elazar E, Akirav I (2009). "Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance". J. Neurosci 29 (36): 11078–88. doi:10.1523/JNEUROSCI.1223-09.2009. PMID 19741114. Lay summary – PsychCentral (5 November 2009). 
  50. PMID 17157480 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  51. PMID 16173972 (PubMed)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  52. Carley DW, Paviovic S, Janelidze M, Radulovacki M (2002). "Functional role for cannabinoids in respiratory stability during sleep". Sleep 25 (4): 391–8. PMID 12071539. http://www.scholaruniverse.com/ncbi-linkout?id=12071539. 
  53. Grotenhermen, Russo (2002) "Review of Therapeutic Effects." Chapter 11, p. 128 in Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential, Routledge, ISBN 0789015080.
  54. Salazar M; Carracedo A; Salanueva IJ; Cecconi, Sonia; Pandolfi, Mar; González-Feria, Ainara; Iovanna, Patricia; Guzmán, Cristina et al. (2009). "Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells". The Journal of Clinical Investigation 119 (5): 1359–72. doi:10.1172/JCI37948. . PMID 19425170. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2673842. Lay summary – HealthDay (1 April 2009). 
  55. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). "Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells". Molecular Cancer Therapeutics 6 (11): 2921–7. doi:10.1158/1535-7163.MCT-07-0371. PMID 18025276. Lay summary – BBC News (19 November 2007). 
  56. McAllister SD, Murase R, Christian RT, et al. (22 September 2010). "Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis". Breast Cancer Res Treat. 129 (1): 37–47. doi:10.1007/s10549-010-1177-4. . PMID 20859676. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3410650. Nakuha noong 2012-12-24.